News | May 02, 2014

Late-Breaking Trials to be Presented at SCAI Announced

Late-Breaking Trials SCAI May 2014

May 2, 2014 — The Society for Cardiovascular Angiography and Interventions (SCAI) announced the late-breaking clinic al trial data presentations for it its upcoming 2014 Scientific Sessions, May 28-31, in Las Vegas. The late-breaking clinical trials will be presented Friday, May 30, from 2-3 p.m. PST. These are:

• Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization: The Radiation Reduction during Cardiac Catheterization Using Real Time Monitoring (RadiCure) Study, presented by Georgios Christopoulos, M.D.

• Diamondback 360° Coronary Orbital Atherectomy System for Treating De Novo, Severely Calcified Lesions: ORBIT II 1-Year Results and Cost Comparison to a Sample of Medicare Hospital Claims, presented by Jeffrey Chambers, M.D., FSCAI

• Comparison of Lesion Level Decision Making in the Cath Lab Using Hyperemic and Non-Hyperemic Pressure Wire Derived Indices of Stenosis Severity: The VERIFY-2 Study, presented by Stuart Watkins, M.D.

• 3-Dimensional Quantitative Coronary Angiography Using Coronary Catheters as Objective Markers Reliably Unmasks Severe Occult Stenosis in Diffusely Diseased Vessels: New Results from the IQ-CATEGORIZE Lesions Study, presented by Charles Laham, M.D., FSCAI

This year’s keynote speakers will discuss hot topics in interventional cardiology, including the challenges and opportunities today’s professionals face:

• Martin Leon, M.D., FSCAI, will focus on the evolution of innovation in interventional cardiology. Leon’s remarks will touch on the past and present of the field, but will emphasize the future of one of the most rapidly evolving, cutting-edge areas of medicine and the role of each professional in continuing to break new ground in ever-improving patient care.

• Pediatric interventional cardiologist James E. Lock, M.D., will address the obstacles involved in development of new and effective treatments for the littlest hearts, including clinical trial execution. Lock will discuss his step-by-step process for successful innovation amidst these challenges and will challenge the interventional cardiology community to innovate, offering kids the best chance to grow and thrive.  

• Patrick T. O’Gara, M.D., will explore the dynamic challenges facing the cardiovascular workforce, including restrictions to Medicare-based funding for residencies and the growing gap between the demand for cardiovascular specialists and the supply. O’Gara also will present practical solutions for interventional cardiologists and their practices to implement as the healthcare environment continues to evolve.

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init